Ø
Ø
Ø
Ø
Ø Virus-Agnostic Therapeutic for COVID-19, Influenza,
Related Diseases and Future Viral Pandemic Outbreaks.
Q
BioMed, Inc. (OTCQB: QBIO), is a biotech acceleration and commercial
stage company focused on licensing and acquiring undervalued biomedical assets
in the healthcare sector. QBIO is dedicated to providing these target
assets the strategic resources, developmental support, and expansion capital
needed to ensure they meet their developmental potential, enabling them to
provide products to patients in need.
QBIO aims to accelerate the monetization of biomedical
technologies through rapid innovation and collaborative partnerships with
industry leading researchers. QBIO believes its assets in oncology,
vascular disease, and rare orphan diseases address unmet medical needs and
large markets.
QBIO launched its FDA approved, non-opioid drug
Strontium89, which relieves bone pain from cancer metastases, in February 2020.
Strontium89 is also approved for sale in 21 other countries. The QBIO
robust clinical pipeline is expected to produce growing revenues for the company
and value infection points for investors.
Ø Strontium89 Will be Available in September 2020 Through
Named Patient Program for Bone Metastases Pain Palliation in EU and Globally
On
August 11th QBIO announced launching a Named Patient Program
for its non-opioid bone metastases pain palliation drug, Strontium89 (Strontium
Chloride Sr-89 Injection, USP). The Named Patient Program will be available to
physicians and patients in the EU and throughout the world, and will be
facilitated by Caligor
Coghlan Pharma Services (CCPS).
Strontium89
is indicated for the treatment of painful skeletal metastases caused by cancer,
and is agnostic of the primary tumor. Common primary tumors that metastasize to
the bone include prostate, breast, lung, as well as others. In several
multicenter, placebo-controlled trials in cancer patients with pain from bone
metastases, pain relief occurred in more patients treated with a single
injection of Strontium89 than in patients treated with an injection of placebo.
Strontium89 is administered intravenously once every three months and for some
patients can reduce or even eliminate the need for opioid analgesics; pain
relief lasts from 2 - 5 months in most patients.
Over
ten million people around the world suffer from pain associated with metastatic
cancer in the bone and may benefit from Strontium89. For nearly two years,
there has been little to no access to this vital therapy, after manufacturing
ceased in December of 2018. QBIO is pleased that the Named Patient
Program will ensure immediate global patient access to an important therapy for
this patient population. In the meantime, QBIO is actively pursuing full
regulatory and marketing approval for Strontium89 in all major markets
worldwide.
Ø
On
July 22nd QBIO and Chemveda Life Sciences announced continued
collaboration on Uttroside-B, a chemotherapeutic that has shown remarkable
potential efficacy as a treatment for liver cancer. While focused on its
commercial rollout of Strontium89, this drug development program will advance
another important asset in the QBIO portfolio towards monetization. The
efficacy of Uttroside-B, a potent saponin, against liver cancer was
demonstrated in a preclinical study published in the November
2016 issue of Scientific Reports, a Nature journal.
Ø
On
June 30th QBIO issued a Shareholder Update Letter which included
information on a high potential treatment for critical virus based diseases. Technology
partner Mannin Research Inc. (Mannin) was recently granted up to $7.7
million in Europe, which will fund 65 percent of every dollar
incurred to advance a portfolio of therapeutic assets for vascular diseases
currently in development at Mannin, including: glaucoma, cardiovascular
diseases, acute kidney disease, and infectious diseases such as influenza and
coronavirus, among others.
Given
the urgent need for therapeutics to treat COVID-19, Mannin is rapidly
accelerating the time to the first clinical milestone for MAN-19. An
Investigational New Drug (IND) application (or similar clinical trial proposal)
to regulators are planned for late 2020. It is important to note that the
MAN-19 therapeutic is virus-agnostic, which makes it relevant to other viral
diseases today like influenza and future viral pandemic outbreaks. Therefore, a
successful infectious disease application in COVID-19 would position MAN-19
very well as a potential government stockpile drug for inevitable future
pandemics. Furthermore, a successful proof-of-concept clinical trial with
MAN-19 in COVID-19 patients would provide the clinical dataset to quickly
support the development of therapeutics for other vascular diseases such as
sepsis, acute kidney injury, and of course glaucoma. All of these are very
large markets with significant potential.
For
more information on Q BioMed, Inc. (QBIO) visit: http://www.QBioMed.com
